Clinical Trial Update: Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating trastuzumab for previously treated, locally advanced or metastatic urothelial cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Distal Urethral Cancer
• Proximal Urethral Cancer
• Urethral Cancer
• Urothelial Cancer
• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter

Drugs mentioned

• Trastuzumab (trastuzumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter | Phase 2 | Status: TERMINATED